Fredun Pharmaceuticals Limited

About

Fredun Pharmaceuticals Limited manufactures and sells pharmaceutical formulations, dietary/herbal supplements, nutraceuticals, animal healthcare products, cosmeceuticals, mobility and rehabilitation products, and other healthcare products in India, Africa, Southeast Asia, Commonwealth of Independent States countries, MENA region, and Latin America. The company offers allopathic formulations, including analgesics/NSAID, antacid/antiulcer, anthelmintic, antibacterial, anti-diabetic, anti-inflammatory, anti-malarial, anti-obesity, antacid, anthelmintic, anticoagulants, anticonvulsants, antidiarrhoeal, antidepressant, antifungal, antihistamines/antiallergic, antihypertensives, antiviral, bone modulating drugs, bronchodilators and anti-asthma drugs, calcium tablets, cardiovascular, diuretic, impotence drugs, laxative, and appetite stimulant with multivitamins. It also provides surgical products, such as IV fluids and cannulas, disposable syringes, infusion sets, surgical gloves and cottons, and personal healthcare products; APIs; direct compressible granules; pellets; animal healthcare products; aqua products; and niche products. Additionally, the company offers therapeutic products under the brand Hormone Range Products, a specialty therapeutics brand focused on longevity, hormone health, recovery science, and human performance solutions. Fredun Pharmaceuticals Limited was incorporated in 1987 and is headquartered in Mumbai, India.,

Key Metrics

as of Sep 2026

Market Cap2,432 Cr

P/E55.50

Div Yield0.02 %

Book Value₹170.00

52w High₹1,600.00

52w Low₹391.00

Face Value₹10.00

Quarterly Results

Rs. Crores · hover row for definition

Metric	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023
Sales	228.00	213.00	161.00	145.00	120.00	167.00	103.00	107.00	79.00	118.00	87.00	82.00	62.00
Expenses	195.00	184.00	135.00	123.00	103.00	150.00	89.00	93.00	68.00	107.00	76.00	72.00	54.00
Operating Profit	33.00	29.00	26.00	22.00	17.00	17.00	13.00	14.00	10.00	11.00	11.00	10.00	8.00
OPM %	14.00	14.00	16.00	15.00	14.00	10.00	13.00	13.00	13.00	9.00	12.00	12.00	12.00
Other Income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation	4.00	3.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Interest	9.00	14.00	11.00	8.00	7.00	8.00	5.00	5.00	4.00	4.00	4.00	3.00	3.00
Profit before tax	21.00	12.00	14.00	13.00	9.00	8.00	7.00	8.00	6.00	6.00	6.00	6.00	4.00
Tax %	36.00	4.00	25.00	25.00	25.00	12.00	25.00	44.00	25.00	13.00	27.00	32.00	41.00
Net Profit	13.00	11.00	10.00	10.00	7.00	7.00	5.00	4.00	4.00	5.00	4.00	4.00	2.00
EPS in Rs	7.98	6.75	6.51	6.85	4.77	4.98	3.75	3.01	2.91	3.59	2.99	2.79	1.75

Profit & Loss

Annual · Rs. Crores

Metric	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015
Sales	635.00	454.00	348.00	275.00	222.00	134.00	113.00	97.00	60.00	57.00	42.00	25.00
Expenses	544.00	401.00	310.00	247.00	208.00	126.00	104.00	87.00	54.00	53.00	38.00	24.00
Operating Profit	91.00	53.00	38.00	28.00	14.00	8.00	8.00	10.00	6.00	3.00	4.00	2.00
OPM %	14.00	12.00	11.00	10.00	6.00	6.00	7.00	11.00	10.00	6.00	9.00	7.00
Other Income	4.00	2.00	1.00	2.00	2.00	1.00	1.00	0.00	0.00	2.00	1.00	0.00
Interest	39.00	22.00	14.00	9.00	5.00	4.00	4.00	3.00	2.00	2.00	2.00	1.00
Depreciation	8.00	4.00	4.00	3.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00
Profit before tax	48.00	28.00	21.00	18.00	9.00	3.00	2.00	6.00	3.00	2.00	2.00	1.00
Tax %	30.00	26.00	27.00	38.00	26.00	37.00	24.00	28.00	34.00	36.00	42.00	52.00
Net Profit	33.00	21.00	16.00	11.00	6.00	2.00	2.00	4.00	2.00	1.00	1.00	0.00
EPS in Rs	20.25	14.65	11.08	7.95	4.77	1.68	1.58	3.72	1.70	2.01	1.51	0.37
Dividend Payout %	1.00	2.00	2.00	3.00	5.00	14.00	14.00	6.00	12.00	10.00	13.00	0.00

Balance Sheet

Annual · Rs. Crores — latest first

Metric	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015
Equity Capital	5.00	5.00	5.00	5.00	4.00	4.00	4.00	4.00	3.00	2.00	2.00	2.00
Reserves	273.00	137.00	117.00	92.00	64.00	39.00	37.00	35.00	19.00	2.00	1.00	0.00
Borrowings	222.00	166.00	106.00	87.00	53.00	40.00	35.00	19.00	10.00	21.00	16.00	9.00
Other Liabilities	141.00	179.00	81.00	74.00	66.00	79.00	65.00	47.00	47.00	30.00	24.00	11.00
Total Liabilities	642.00	487.00	308.00	257.00	187.00	162.00	141.00	105.00	79.00	56.00	43.00	23.00
Fixed Assets	118.00	53.00	47.00	39.00	32.00	30.00	31.00	31.00	16.00	16.00	15.00	8.00
CWIP	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	11.00	4.00	0.00	1.00
Investments	2.00	2.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Assets	522.00	433.00	260.00	218.00	155.00	131.00	110.00	74.00	52.00	36.00	29.00	14.00
Total Assets	642.00	487.00	308.00	257.00	187.00	162.00	141.00	105.00	79.00	56.00	43.00	23.00

Cash Flows

Annual · Rs. Crores — latest first

Metric	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015
Cash from Operating Activity	16.00	-21.00	0.00	-14.00	-2.00	0.00	-11.00	1.00	17.00	4.00	3.00	2.00
Cash from Investing Activity	-74.00	-6.00	-8.00	-9.00	-4.00	-1.00	-1.00	-5.00	-8.00	-7.00	-6.00	-3.00
Cash from Financing Activity	122.00	26.00	6.00	25.00	7.00	-1.00	14.00	4.00	-8.00	3.00	3.00	1.00
Net Cash Flow	65.00	-1.00	-2.00	1.00	1.00	-2.00	2.00	0.00	1.00	-1.00	1.00	0.00
Free Cash Flow	-57.00	-27.00	-8.00	-24.00	-7.00	-1.00	-12.00	-4.00	9.00	-3.00	-3.00	-1.00
CFO/OP %	18.00	-43.00	-1.00	-52.00	-17.00	2.00	-128.00	8.00	303.00	117.00	85.00	108.00

Ratios

Annual · Days / % — latest first

Metric	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015
Debtor Days	53.00	142.00	68.00	46.00	148.00	112.00	126.00	67.00	94.00	131.00	98.00	75.00
Inventory Days	219.00	267.00	246.00	264.00	96.00	242.00	227.00	249.00	170.00	68.00	140.00	102.00
Days Payable	71.00	161.00	88.00	104.00	101.00	215.00	208.00	205.00	360.00	224.00	221.00	167.00
Cash Conversion Cycle	201.00	248.00	225.00	205.00	144.00	139.00	145.00	110.00	-96.00	-24.00	17.00	11.00
Working Capital Days	79.00	76.00	92.00	97.00	126.00	116.00	65.00	66.00	42.00	-39.00	-44.00	-54.00
ROCE %	21.00	19.00	17.00	18.00	13.00	10.00	10.00	21.00	16.00	18.00	25.00	14.00

Shareholding Pattern

% holding — latest first

Holder	Jul 2026	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023
Promoters	44.57	44.57	44.17	43.06	48.93	48.93	48.93	48.93	48.93	49.17	49.17	49.16
FIIs	1.06	1.06	1.06	0.46	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00
DIIs	2.94	2.94	2.83	3.48	1.61	1.59	1.59	1.59	1.59	1.60	1.60	1.60
Public	51.43	51.45	51.94	53.00	49.46	49.49	49.47	49.47	49.47	49.23	49.24	49.24
No. of Shareholders	9,598	8,903	8,338	8,765	8,120	7,906	7,976	8,121	8,018	7,511	7,507	6,837

Corporate Actions

12 records

Action	Ex Date	Record Date	Ratio	Amount (₹)	Notes
Bonus	16 Jul 2026	16 Jul 2026	2:1	—
Dividend	23 Jun 2026	23 Jun 2026	—	0.70
Dividend	23 Sep 2025	23 Sep 2025	—	0.70
Dividend	23 Sep 2024	23 Sep 2024	—	0.70
Other	11 Jan 2024	—	—	—	E.G.M.
Dividend	22 Sep 2023	22 Sep 2023	—	0.70
Dividend	16 Sep 2021	—	—	0.70
Dividend	18 Sep 2020	21 Sep 2020	—	0.66
Dividend	16 Sep 2019	—	—	0.65
Dividend	18 Sep 2018	—	—	0.60
Dividend	20 Sep 2017	—	—	0.60
Dividend	11 Apr 2016	—	—	0.60

Announcements

5 filings

Announcement under Regulation 30 (LODR)-Press Release / Media Release
04 Sep 2026 4 Sep - Fredun Pharmaceuticals launches PAWTALKS, a pet and animal healthcare knowledge platform on YouTube and Instagram.
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
17 Aug 2026 17 Aug - Transcript of the Earnings Conference call held on 13th August, 2026 for Q1 FY27.
Intimation Regarding Permission To Trade And Admission Of Equity Shares To Dealings On The National Stock Exchange Of India Limited.
17 Aug 2026 17 Aug - Fredun Pharmaceuticals shares permitted to trade on NSE from August 17, 2026; symbol FREDUN.
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
14 Aug 2026 14 Aug - CARE report flags Rs 13.21 crore deviation and unutilized proceeds mismatch for quarters ended Mar and Jun 2026.
Statement Of Deviation Or Variation For The Quarter Ended June 30, 2026
14 Aug 2026 14 Aug - Fredun reports no deviation in ₹111.53 crore preferential issue proceeds for quarter ended June 30, 2026.